Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xenon Pharmaceuticals Inc XENE

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the... see more

Recent & Breaking News (NDAQ:XENE)

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire April 25, 2022

Xenon Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

GlobeNewswire April 4, 2022

Xenon Pharmaceuticals to Present at Stifel 2022 CNS Days

GlobeNewswire March 22, 2022

Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 1, 2022

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate Update

GlobeNewswire February 22, 2022

Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 14, 2022

Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone

GlobeNewswire January 12, 2022

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022

GlobeNewswire January 10, 2022

Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b 'X-TOLE' Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)

GlobeNewswire December 3, 2021

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2021)

GlobeNewswire December 3, 2021

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire November 12, 2021

Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2021

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update

GlobeNewswire November 3, 2021

Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire October 8, 2021

Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering

GlobeNewswire October 5, 2021

Xenon Pharmaceuticals Announces Proposed Public Offering

GlobeNewswire October 4, 2021

Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b 'X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy

GlobeNewswire October 4, 2021

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b 'X-TOLE' Clinical Trial of XEN1101

GlobeNewswire October 3, 2021

Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone

GlobeNewswire September 8, 2021

Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer

GlobeNewswire August 23, 2021